Swiss Economic Forum labels Redbiotec as High Potential SME
Schlieren, 18 February 2013
We are pleased to announce that Redbiotec has been labeled "High Potential SME" by the Swiss Economic Forum (SEF) through a certified process. This is a further proof for Redbiotec's high value business.
New agreement with Roche
Schlieren, 07 December 2012
Redbiotec AG has signed a new agreement with Roche Diagnostics GmbH, Germany, under which it will apply its proprietary technology platform rePAX® to produce VLPs. Roche intends to use the VLPs in an antibody discovery program in an undisclosed area.
Successful proof of concept study with Intercell AG
Schlieren, 06 December 2012
Intercell and Redbiotec have successfully completed the proof of concept study, in which Redbiotec has applied its proprietary technology platform rePAX® in an undisclosed discovery area. Redbiotec looks forward to continue its collaboration with Intercell.
Growing interest in Redbiotec’s CMV program
Schlieren, 18 September 2012
Redbiotec has been selected to present its CMV Vaccine program at the CMV 2012 Meeting in San Francisco starting October 31. Pharma companies including Novartis, Sanofi Pasteur, MedImmune, Boehringer Ingelheim with leading CMV activities will also join the meeting.
Redbiotec extends deal with Merck
Schlieren, 27 August 2012
Redbiotec is pleased to announce that the project started with Merck Sharp & Dohme Corp. (NJ, USA) in October 2011, in which Redbiotec applies its proprietary technology platform rePAX® to an undisclosed discovery area, has reached a first milestone successfully and was therefore extended. We look forward to the ongoing collaboration with Merck!
Redbiotec closes initial agreement in the field of prime-boost
Schlieren, 24 August 2012
Redbiotec today announced that it has closed an agreement with a listed, leading biopharmaceutical company in the field of prime-boost for cancer therapeutics to validate the approach. Christian Schaub, CEO of Redbiotec, states: “This is a major step for Redbiotec and a further proof of Redbiotec’s leadership in the development and production of complex VLPs.” Redbiotec develops VLPs for three main fields: 1) VLP vaccines, 2) VLPs for prime-boost / enhancement of cancer therapeutics and 3) VLPs, expressing GPCRs and ion channels, as targets for antibody screening.
New deal with antibody company
Schlieren, 19 July 2012
Redbiotec today announced that it has closed a new collaboration agreement with an undisclosed company in the field of antibody generation. The goal of this collaboration is the development of new therapeutic antibodies using Redbiotec’s VLPs as targets. Under the agreement, the parties will share profit generated by the therapeutic antibodies.
Challenge experiments successfully finalized
Schlieren, 10 May 2012
The challenge experiment using Redbiotec’s tetravalent influenza VLPs was successfully finalized. Results obtained clearly show that influenza VLPs are capable of stimulating the humoral and cellular immune responses which neutralize and inhibit replication of a challenge virus. When immunized mice were challenged with a lethal dose of the parental virus, 100% of mice were protected.
Redbiotec signs feasibility study with 4-Antibody AG
Schlieren, 17 February 2012
Redbiotec is pleased to announce that it has entered into a collaboration with 4-Antibody, in which Redbiotec will apply its proprietary technology platform rePAX® to an undisclosed discovery area. This agreement is a further validation of the application of Redbiotec’s VLPs in antibody generation.
Prof. Roy awarded gold medal for science
Schlieren, 24 January 2012
Redbiotec and DKFZ extend collaboration
Schlieren, 17 January 2012
The German Cancer Research Institute (DKFZ) and Redbiotec have extended their collaboration in the field of HPV, which started in 2009. Goal of the collaboration is the validation of chimeric VLPs, containing proteins of different serotypes on one VLP.
Influenza challenge shows protection of Redbiotec's VLPs
Schlieren, 14 December 2011
For the proof-of-principle, influenza A/PR/8/34 VLPs carrying four parental proteins were tested in a mouse challenge model. Preliminary results show that Redbiotec’s influenza-VLPs effectively protect the immunized mice against the parental challenge virus. Please contact us for more information to these study results.
Redbiotec signs exploratory study with Intercell AG
Schlieren, 06 December 2011
Redbiotec top ranked
Schlieren, 27 October 2011
We are proud to announce that Redbiotec has been voted 13th out of all Swiss start-up companies founded since 2006. The ranking is based on the evaluation of 100 Experts in the start-up scene. Start-up companies from all sectors (incl. IT, Cleantech and others) were evaluated. For further information, please see http://www.startup.ch.
Redbiotec closes deal with Merck
Schlieren, 06 October 2011
Redbiotec at the BioValley Life Sciences Week
Schlieren, 12 September 2011
Redbiotec CEO Christian Schaub has been invited to participate in the panel discussion at the Biotech Connect Day September 22 in the BioValley LifeSciences Week 2011. The BioValley Life Sciences Week is the annual networking platform for the regional Life Sciences Community in the trinational Basel area.
Redbiotec enters into perennial collaboration agreement
Schlieren, 21 July 2011
New business developer hired
Schlieren, 28 March 2011
Mrs Nila-Pia Raehle, formerly working for Ypsomed and Synthes, was hired in order to strengthen Redbiotec's business development. Nila has over 10 years experience in product management and deal making with pharma companies.
Schlieren, 28 March 2011
Redbiotec has rented 200 additional square meters of lab and office space. Till end of Q2 2011 Redbiotec will implement new cutting edge technologies into its leading rePAX® platform, including the ÄKTA avant system (GE Healthcare).
Redbiotec closes deal with Roche
Schlieren, 02 December 2010
Redbiotec closes deal with Roche. Redbiotec AG, the leader in protein complexes and designer virus-like particles (VLP) enters into a collaboration with Roche, by which it will apply its proprietary technology platform [rePAX®] to an undisclosed discovery area. After having successfully worked for two leading global vaccine players in 2010, the deal with Roche is an additional highlight of a successful year for Redbiotec.
New purification expert
Schlieren, 01 November 2010
We are proud to announce that in November 1st Dr. Tiago Vicente, joined Redbiotec as purification expert. With his strong background in downstream processing Dr. Vicente will implement specific purification methods and processes for Redbiotec's new designer VLPs, particularly in the field of Herpesviruses.
Redbiotec obtains new grant
Schlieren, 26 August 2010
Redbiotec obtains a new grant. The grant is a initiative with the Group of Prof. Wilfried Weber, University of Freiburg, to explore further applications of Redbiotec’s REPAX™ technology.
Redbiotec launches CMV VLP program
Schlieren, 08 June 2010
Redbiotec has launched the development of several multi-valent virus-like particles (VLPs) against the Cytomegalovirus (CMV).
Redbiotec Strengthens its Scientific Advisory Board with Appointments of Professor Dr. Polly Roy and Professor Dr. Rainer Fischer
Schlieren, 19 May 2010
Redbiotec AG ("Redbiotec" or "the Company"), the leader in protein complexes and designer virus-like particles (VLP), today announces two new appointments to its Scientific Advisory Board. Professor Polly Roy, one of the world’s leading baculovirus specialists, and Professor Rainer Fischer, an expert in molecular immunology and molecular biotechnology, bring extensive experience and knowledge in protein engineering and in VLP-based vaccine approaches.
V+ invests in Redbiotec
Schlieren, 19 April 2010
V+ GmbH & Co Fonds 2 KG, a German Venture Capital fund invests in Redbiotec. The investment strengthens the leading position of Redbiotec in designer virus-like particles (VLPs) and protein complexes. Solidly financed, Redbiotec is applying its unique CAP ® technology for the development of additional novel vaccine and biologic candidates.
Redbiotec's technology platform raises substantial interest
Schlieren, 13 January 2010
On the occasion of BioEurope 2009 in Vienna, Europe's most important Pharma and Biotech partnering conference, Redbiotec presented its proprietary and cutting-edge protein expression technologies to the international community. Important contacts were established with leading Pharma and Biotech companies. Redbiotec is now in advanced negotiations with several of these regarding the use of its technologies for vaccine development and drug discovery. Redbiotec will also be present at the follow-on conference, BioEurope Spring 2010, in Barcelona.
Successful in vivo test of influenza particles
Schlieren, 15 October 2009
In Q4 2009 Redbiotec demonstrated a specific immune response of its nature-like influenza virus-like particles in mice. The particles represent an ideal vaccine candidate as they contain all major virus antigens in one virus-like particle.
Implementation of disposable technologies
Schlieren, 25 June 2009
Redbiotec has successfully implemented novel disposable production technologies into its leading technology platform. These technologies garantee process efficiency with high scalability.
Schlieren, 20 June 2009
Starting in April 2009 we increased our total space to 300 m2. Thanks to this expansion we could double our laboratory space. The operations in the new lab space were successfully started in May 2009.
New Senior Scientist at Redbiotec
Schlieren, 03 April 2009
We are proud to announce that in April 1st Dr. Armando Zuniga, formerly at Crucell / Berna Biotech, joined Redbiotec as Senior Scientist. With his strong background in pre-clinical development Dr. Zuniga is responsible for the veterinary business line and for the generation and validation of animal data of Redbiotec’s vaccine candidates.
Nobel Prize awarded for discovering that Human Papilloma Virus causes cervical cancer
Schlieren, 07 October 2008
On October 6 the Nobel Assembly in Sweden awarded half of the Nobel Prize in Physiology or Medicine 2008 to Harald Zur Hausen from Deutsches Krebsforschungszentrum (DKFZ).Redbiotec is developing improved vaccines against the Human Papilloma Virus using our unique expression technology for the production of complex virus-like particles.
3 new advisory board members
Schlieren, 09 September 2008
Redbiotec recently added 3 new prominent members to our already outstanding advisory board. Among the new advisors is Dr. Reinhard Glück, president of the Swiss Biotech Association and Executive Vice President R&D, Vaccine Discovery, Crucell - Berna Biotech.
Redbiotec uses expression technology for production of virus like particles (VLPs)
Schlieren, 02 May 2008
Recently, Redbiotec moved into the area of vaccine development by applying the unique expression technology to production of VLPs. To strengthen our position in this area, Dr. Sabine Wellnitz, formerly at Novartis and Roche, joined Redbiotec as a senior research scientist with a strong background in VLP production in insect cells.
Collaboration with ETH Zurich - Expression of IKK-Complexes
Schlieren, 29 February 2008
Redbiotec is collaborating with ETH Zurich in testing advantages of co-expression using IkappaB kinase (IKK) as an example. Activity of several IKK complex variations will be tested.
Collaboration with the University of St. Gallen
Schlieren, 26 February 2008
Biopharmaceuticals - i.e. protein based drugs - are one of the fastet growing type of drugs and expertise on the industrial production will be increasingly sought off. Thus Redbiotec started a collaboration with the department of Prof. Dr. Thierry Voléry from the University of St. Gallen in the form of a master thesis.In the next 6 month to come current industrial production processes will be systematically analysed upon optimization potential through the leading baculovirus technology of redbiotec.
First successful industrial project
Schlieren, 04 June 2007
Redbiotec has successfully expressed difficult to produce proteins - kinases - for the german biotech company Crelux. The proteins are being used as drug targets for the discovery of pharmaceuticals.Though time was short, Redbiotec mastered the challenge of significantly increasing the yield. „Redbiotec has been the perfect partner for our challenging projects.Therefore we will tighten our collaboration in the future." Dr. Ismail Moarefi, Chief Scientific OfficerCrelux, Munich
Hiring people for research and development
Schlieren, 06 February 2007
Redbiotec is strengthening its team by hiring highly qualified people in research and development.
First industrial customer
Schlieren, 29 January 2007
Rebiotec sealed its first work contract deals with an industrial customer and is actively pursuing negotiations with other potential customers in the pharma/ biotech sectors.
New office und laboratory
Schlieren, 01 January 2007
Redbiotec opened its new office and laboratory in Schlieren, near Zurich, alongside an established core of several successful bioech companies.
Support through the Volkswirtschaftsstiftung
Schlieren, 27 November 2006
Redbiotec has received financial support through the Volkswirtschaftsstiftung.
Exclusive license deal with ETH Zürich
Schlieren, 03 November 2006
Redbiotec has negotiated an exclusive license deal with the ETH Zürich over patented MultiBac technology and the ETH has now become a partner and shareholde of Redbiotec.
Incorporation as Aktiengesellschaft (AG)
Schlieren, 03 November 2006
Redbiotec was incoporated as an Aktiengesellschaft. All founders of the patented MultiBac technology are shareholders of Redbiotec AG. Soon the ETH Zürich will become shareholder too.
Second prize Venture 2006
Schlieren, 09 June 2006
Under the former name XpresSys the team of Redbiotec wins the second prize of the Venture 2006. This success is based on the excellent businessplan, the attractive technology and on the strong founder team. Redbiotec was superior on nearly 100 other projects.Venture 2006 is an initiative of the ETH Zurich and McKinsey & Company, Switzerland. The Swiss-wide business plan competition supports young entrepreneurs in founding a company. Venture 2006 – as did Venture 98, 2000, 2002 and 2004 – aims to put to use untapped innovation potential by encouraging young entrepreneurs to develop a business idea. A number of renowned companies from Swiss industry and commerce sponsor the competition.